Increasing use of hydroxyurea for sickle cell in Nigeria
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study aims to help more people with sickle cell disease in Nigeria start taking hydroxyurea, a medicine that can prevent pain crises and other complications. It will work with clinics to make it easier for patients to get and stay on this treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have sickle cell disease (any type, including SS, Sβo thal, or SOArab; some with SC may also qualify).
- You are at least 12 months old (children with a guardian or adults 18+).
- You are registered and receiving care at a participating clinic in Nigeria.
- You are not currently taking hydroxyurea.
- You are willing and able to take part in study activities like appointments and follow-ups.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how people of Nigerian descent with sickle cell disease respond to hydroxyurea, a medicine that helps prevent painful episodes. The goal is to see how your genetic makeup affects how the drug works so that doctors can find the best dose for you.
This trial tests a new twice-daily liquid form of hydroxyurea (a common SCD medicine) in children ages 9 months to 11 years with sickle cell disease. It will check how the medicine works in the body, if it is safe, and if it helps reduce pain crises and other complications.
This trial program studies sickle cell disease and how treatment works, especially for people who are already taking hydroxyurea at a stable, maximum tolerated dose. It may help researchers better understand treatment effects and side effects in real patients.
This trial tests a way to use hydroxyurea more safely and effectively in children with sickle cell anemia. It may help doctors fine-tune dosing to reduce complications and side effects.
This trial tests whether giving hydroxyurea (a medicine that helps prevent strokes) to children with sickle cell disease who have high-risk blood flow in their brains can stop strokes from happening. It's for kids in Nigeria who are at the peak age for stroke risk (5–12 years old).
This study tests how well a higher dose of hydroxyurea works for teenagers with sickle cell anemia living in areas where malaria is common. It looks at safety and how the treatment affects their daily lives.
Hear when a new Sickle Cell Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.